z-logo
open-access-imgOpen Access
Regulating off-label drug use in India: The arena for concern
Author(s) -
Sukhvinder Singh Oberoi
Publication year - 2015
Publication title -
perspectives in clinical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 8
eISSN - 2229-5488
pISSN - 2229-3485
DOI - 10.4103/2229-3485.159935
Subject(s) - off label use , orphan drug , promotion (chess) , drug , medicine , alternative medicine , intensive care medicine , business , quality (philosophy) , population , risk analysis (engineering) , internet privacy , pharmacology , computer science , environmental health , bioinformatics , political science , philosophy , epistemology , pathology , politics , law , biology
Off-label use of drugs is relatively common in medical practice, even if it's often not supported by strong scientific evidence. Off-label use of medicine not only involves physicians and pharmaceutical companies, but regulatory agencies and patients as well. Therapeutic options might get restricted without off-label prescribing in some patient population. Off-label uses can be useful to patients with an orphan disease where sometimes it can be the only available treatment. Permitting the promotion of drugs for off-label uses may be appropriate in instances in which a drug can improve the quality (e.g., same or better outcomes at lower cost). Although many controversies exist, experts generally agree that further efforts are needed to increase access to suitable off-label drugs for patients with rare and other diseases. However, they also concur that potential inappropriate promotion, as well as possibly dangerous prescribing practices for these drugs, should be prevented. Proponents argue that the key benefit of allowing manufacturers to distribute off-label information is that it allows more data to be readily available to physicians, enabling them to make better treatment decisions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here